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OBJECTIVE — To test the hypothesis that exenatide twice daily reduces the relative inci-
dence of cardiovascular disease (CVD) events among patients with type 2 diabetes compared
with other glucose-lowering agent(s).
RESEARCH DESIGN AND METHODS — A retrospective database analysis was per-
formed of the LifeLink database of medical and pharmaceutical insurance claims for June 2005
through March 2009. Patients with no history in the preceding 9 months of myocardial infarc-
tion, ischemic stroke, or coronary revascularization procedure were assigned to the exenatide-
initiated or non–exenatide-initiated cohorts based on the ﬁrst new prescription ﬁlled and
reassigned if exenatide was prescribed or discontinued. Incident CVD events (myocardial in-
farction,ischemicstroke,orcoronaryrevascularizationprocedure)wereidentiﬁedbyICD-9-CM
diagnosis codes. Patient outcomes were adjusted for differences in clinical and demographic
characteristics and compared using propensity score–weighted discrete time survival analysis
with time-varying exposure to exenatide.
RESULTS — Atotalof39,275patientswithtype2diabetesweretreatedwithexenatidetwice
daily, and 381,218 patients were treated with other glucose-lowering therapies. Patients who
initiated exenatide were more likely to have prior ischemic heart disease, obesity, hyperlipid-
emia, hypertension, and/or other comorbidities at baseline. Exenatide-treated patients were less
likely to have a CVD event than non–exenatide-treated patients (hazard ratio 0.81; 95% CI
0.68–0.95; P  0.01) and lower rates of CVD-related hospitalization (0.88; 0.79–0.98; P 
0.02) and all-cause hospitalization (0.94; 0.91–0.97; P  0.001).
CONCLUSIONS — Exenatidetwice-dailytreatmentwasassociatedwithalowerriskofCVD
events and hospitalizations than treatment with other glucose-lowering therapies.
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T
he risk of cardiovascular disease
(CVD) is increased two- to ﬁvefold
in patients with type 2 diabetes
compared with patients without diabe-
tes.Observationalstudieshavereported
that hyperglycemia (even below the
current diabetes diagnostic threshold)
is associated with increased cardiovas-
cular risk (1–3), but the effects of glu-
cose-lowering strategies on CVD events
in clinical trials have been mixed (4–9).
Intervention studies have shown mod-
est beneﬁt (6,8), no beneﬁt (4,7,9), or a
suggestion of harm (5). Furthermore,
aggregatingdataviameta-analyses(10–
12) or systemic review (13) have pro-
vided evidence of beneﬁt and
suggestion of harm. Few data exist on
“real world” experience.
Medicationssuchasexenatidetwice
daily, which have been available to pa-
tients for much shorter periods of time
thansulfonylureasandmetformin,have
not yet been tested in clinical trials of
CVD outcomes. One of the best interval
approaches is to assess the effect of ex-
enatide on CVD outcomes in a “real
world” cohort using well-established
glucose-lowering agents as compara-
tors. This study retrospectively ana-
lyzed the risk of a ﬁrst CVD event
among patients with type 2 diabetes
treated with exenatide or other glucose-
lowering therapies in the LifeLink
database.
Exenatide is an injectable GLP-1 re-
ceptor agonist that was approved in
June 2005 in the U.S. as an adjunct to
diet and exercise for the treatment of
patients with type 2 diabetes who have
not achieved adequate glycemic control
withoutdrugtherapy,onmonotherapy,
or on combination therapy with met-
formin and a sulfonylurea or thiazo-
lidinedione. Exenatide improves
glycemic control, reduces body weight,
and has been associated with improve-
ments in CVD risk factors including hy-
pertension and dyslipidemia in some
but not all patients (14). This study was
designed to test the hypothesis that ex-
enatide use reduces the risk of CVD
events and hospitalization compared
with other glucose-lowering therapies.
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Source population
DatawereobtainedfromtheIMSLifeLink
Program: Health Plan Claims (U.S.) Data-
base (formerly known as PharMetrics),
which is comprised of medical and phar-
maceutical claims for over 36 million
unique patients from 98 health plans
across the U.S for the period June 2005
through March 2009. The database in-
cludesinpatientandoutpatientdiagnoses
(inICD-9-CMformat)andprocedures(in
Current Procedural Terminology, 4th
Edition [CPT-4], and Healthcare Com-
mon Procedure Coding System [HCPCS]
formats) and both retail and mail-order
prescription records. Available data on
prescription claims include the National
Drug Code (NDC), days’ supply, and
quantitydispensed.Datesareavailablefor
all services rendered. Additional data in-
clude demographic variables (age, sex,
geographic region), type of insurance
(e.g., HMO, preferred provider organiza-
tion), payer type (e.g., commercial, self-
pay), provider specialty, and eligibility
dates related to plan enrollment and par-
ticipation. In compliance with the Health
Insurance Portability and Accountability
Act (HIPAA), patient data used in the
analysiswerede-identiﬁed;therefore,this
study was exempt from Institutional Re-
view Board review.
Cohort formation and exposure
deﬁnition
Patients entered the study cohort if they
had type 2 diabetes and ﬁlled any new
glucose-lowering medications on or after
1 June 2005. A new agent was deﬁned as
a prescription ﬁlled with no evidence of a
previous prescription for that agent in the
prior 9 months. Patients were assigned to
the exenatide or nonexenatide cohort
based on the ﬁrst new prescription ﬁlled
on or after 1 June 2005. Patients were de-
ﬁned as having type 2 diabetes if they had
a claim for an oral glucose-lowering med-
ication or exenatide and met at least one
additional criterion during the study pe-
riod: 1) an ICD-9-CM diagnosis code of
250.xx on a medical, facility, or surgical
claimor2)aclaimforinsulinorpramlint-
ide. Patients were excluded from the
studyif1)theywerenotcontinuouslyen-
rolled in a health plan with both medical
andpharmacycoverageforaminimumof
9monthsprecohortentrydateandatleast
1 day postcohort entry date or 2)h a d
acute myocardial infarction (MI), isch-
emic stroke, or coronary revasculariza-
tion procedures during the 9 months
before the cohort entry date (Fig. 1).
Patients were followed from cohort
entry date until the end of their observa-
tionperiod,whichwasdeﬁnedasthedate
of disenrollment, the ﬁrst occurrence of a
CVD event of interest, or end of data
stream(31March2009).Tocapturecom-
plex treatment patterns (e.g., exposure to
glucose-lowering therapy) over time, pa-
tients were allowed to change cohort
membership during the study period. Pa-
tients’ cohort membership was evaluated
at intervals of 31 days. A patient was as-
signed to the exenatide cohort if the day’s
supply for an exenatide prescription plus
31 days covered the end point of the time
interval. As a result, each patient could
have contributed multiple 31-day inter-
vals to the analysis. Patients were desig-
nated as exenatide patients as long as a
prescription for exenatide was found de-
spite the addition or discontinuation of
other glucose-lowering agents, including
insulin. Similarly, nonexenatide patients
were so designated despite switching or
adding glucose-lowering agents different
from the initial agent (except exenatide).
Deﬁnition of study events
CVDeventsofinterestweredeﬁnedasthe
ﬁrst occurrence of MI, ischemic stroke, or
coronary revascularization procedure
(angioplasty/atherectomy, percutaneous
transluminal coronary angioplasty/
stenting, or coronary artery bypass graft).
Incident MI was deﬁned as a hospitaliza-
tion with an ICD-9-CM diagnosis code
(410.xxexcluding410.7x)intheprimary
position. Similarly, ischemic stroke was
deﬁned as a hospitalization with an ICD-
9-CM diagnosis code (433.x1, 434.x1,
435.9, 436, 437.1x, 437.9x) in the pri-
mary position. Coronary revasculariza-
tion procedure was deﬁned as a
hospitalization or an outpatient visit with
oneofthefollowingCPTprocedurecodes
(35450–35459, 35470–35475, 35480–
35495; 92980, 92981, 92982, 92984,
92995, 92996, G0290, G0291, S2211,
S2222; 33510–33536, 33572,
S2204–S2209).
Baseline covariates
Baseline covariates were derived from the
pharmacy and medical claims rendered
duringthe9monthsprecedingcohorten-
try, inclusive of claims rendered during
the day of cohort entry. The following
variables were included: patient demo-
graphics; the calendar quarter of study
entry; indicators of diabetes severity
(number of glucose-lowering medica-
tions used, diabetic retinopathy, periph-
eral neuropathy, renal impairment, and
dialysis); indicators of preexisting CVD
(ischemic heart disease, congestive heart
failure, acute coronary syndrome, deep
veinthrombosis,arrhythmia/conduction-
related events); CVD risk factors (hyper-
lipidemia, hypertriglyceridemia, and
hypertension); other comorbidities (ma-
lignant neoplasms, obesity, depressive
disorders, alcohol dependence/abuse,
smoking, hyperthyroidism, cardiomyop-
athy,cerebrovasculardisease,chronicob-
structive pulmonary disease, asthma,
otherchronickidneydisease,arthritis,os-
teoporosis,andopenheartsurgery),ﬁlled
prescriptions for concomitant therapies
(ACE inhibitors, angiotensin-receptor
blockers, vasodilators, anti-arrhythmic
agents, ﬁbrates, HMG-CoA reductase in-
hibitors [statins], anti-obesity agents, an-
tiplatelet agents, nonsteroidal anti-
inﬂammatory drugs, antithrombolytic
agents, and immunomodulating drugs);
andpatients’Charlsoncomorbidityindex
score (15). The analyses included (and
adjustedfor)variablesthatoccurredmost
frequently (top 50) in the database (pri-
mary and secondary diagnosis codes for
mostrecenthospitalizationpre-exposure,
procedures, ICD-9 diagnosis codes, and
medications), whether they were thought
to be causal or not, to optimize balance
between the study groups.
Data analysis
A propensity score–weighted discrete
time survival analysis with time-varying
exposure to exenatide (16) was used to
compare the hazard of incident CVD
events between patients treated with ex-
enatide versus other glucose-lowering
therapies, which included all formula-
tions of metformin, thiazolidinediones,
sulfonylureas, dipeptidyl-peptidase in-
hibitors,-glucosidaseinhibitors,andin-
sulin.Adatasetwascompiledfromall31-
day intervals contributed by each patient.
A propensity score model was devel-
opedtopredictpatients’assignmentatco-
hort entry to ensure cohort balance. The
propensity score model included 300
variables and the interaction effects de-
rived from the baseline covariates (online
appendices 1–4, available at http://care.
diabetesjournals.org/cgi/content/full/dc10-
1393/DC1). The ﬁnal propensity model
was then used to generate a patient-spe-
ciﬁcpropensityscorethatwasusedtoad-
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To ensure the stability of results with
regard to methodological choices, we
completed a primary analysis and sensi-
tivity analyses that used various designs
and adjustment techniques.
Primary analyses
The primary analysis was a discrete time
survival analysis using time-varying ex-
posure to exenatide. We estimated the
main effect using a propensity score–
weighted pooled logistic regression. The
estimation procedure was completed us-
ing generalized estimating equations to
account for the multiplicity of observa-
tions within patients. The standardized
propensity score weights were calculated
for each patient by the inverse of the pro-
pensityscore,adjustedforthesamplesize
of each cohort.
Sensitivity analyses
Asasensitivityanalysisfortheadjustment
technique, the same model as in the base
casewasestimatedusingpropensityscore
stratiﬁcation as the method of adjust-
ment. Patients were grouped into deciles
based on their estimated propensity
score, and patients were then compared
within each stratum using the pooled lo-
gisticregression.Thesummaryhazardra-
tio (HR) was calculated as a weighted
Figure 1—Patient selection and sample attrition.
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stratum, the weight being the inverse of
the variance of each estimate. The vari-
ance of the weighted average was the in-
verse of the sum of the weights.
Asasensitivityanalysisforthedesign,
we estimated and compared the rate of
CVDeventsusingintent-to-treatanalysis.
The intent-to-treat analysis provides a
goodbenchmarktothegeneralpracticein
a clinical trial and is known to preserve
the null hypothesis.
All data management and analyses
were performed using Statistical Analysis
Software(versions8.2and9.1;SAS,Cary,
NC). For all analyses, statistical signiﬁ-
cance was evaluated at a type 1 error of
5%.
RESULTS— Morethan1.2millionpa-
tients were identiﬁed with evidence of at
least one glucose-lowering prescription
on or after 1 June 2005. After applying all
study criteria, a total of 383,525 patients
prescribed glucose-lowering medications
were included in the analysis (Fig. 1; Ta-
ble 1), including 21,754 exenatide initia-
tors and 361,771 nonexenatide initiators.
Exenatide initiators appeared to have
more severe diabetes based on indicators
ofdiabetesseverity(Table1).Speciﬁcally,
exenatide initiators had evidence of
greater use of other glucose-lowering
therapies before the initial exenatide pre-
scription and a greater proportion of the
exenatide initiators had evidence of dia-
betic retinopathy, peripheral neuropathy,
hyperlipidemia, hypertension, and isch-
emic heart disease than nonexenatide ini-
tiators. Medications used to treat CVD
risk factors were more commonly listed
forexenatideinitiatorsthannonexenatide
initiators, including antihypertensive
agents, antihyperlipidemic agents, and
speciﬁcally ACE inhibitors, angiotensin-
receptor blockers, statins, and ﬁbrates.
Arthritis was the most common comor-
bidity in exenatide initiators, and associ-
atednonsteroidalanti-inﬂammatorydrug
use was also greater. Obesity (ICD-9-CM
code 278.0x) was more prevalent in ex-
enatide initiators than in nonexenatide
initiators.
Cardiovascular events and rate of
hospitalizations
Over the course of the study, 39,275 pa-
tients and 381,218 patients were “ex-
posed” to (treated with) exenatide and
nonexenatide therapies, respectively. The
HR for CVD events among the exenatide-
treated patients compared with the non–
exenatide-treated patients is shown in
Fig. 2. In the primary analysis, exenatide-
treated patients were signiﬁcantly less
likelytohaveaCVDevent(HR0.81;95%
CI 0.68–0.95; P  0.01) compared with
non–exenatide-treated patients. Results
were robust with respect to the statistical
method used. In a propensity score–
stratiﬁed analysis, exenatide-treated pa-
tientswerelesslikelytohaveaCVDevent
(HR 0.80; 0.74–0.86; P  0.001) com-
pared with non–exenatide-treated pa-
tients. In the intent-to-treat analysis,
exenatide initiators were less likely to
Table 1—Baseline clinical characteristics and demographics for patients initiating exenatide
twice daily and other glucose-lowering medications
Exenatide b.i.d. Non-exenatide
Total (n) 21,754 361,771
Mean age (years) 52.7  8.7 53.2  11.2*
Male 43.8 51.5*
Geographic region*
Northeast 29.3 31.1
Midwest 26.7 34.4
South 35.5 24.6
West 8.5 9.9
Health plan type*
Preferred provider organization (PPO) 56.0 46.8
Health maintenance organization (HMO) 24.0 32.7
Point of service (POS) 11.3 13.3
Other/unknown 8.8 7.2
Comorbidities
Indicators of diabetes severity
Diabetic retinopathy 11.2 5.5*
Peripheral neuropathy 4.9 2.7*
Renal impairment 2.8 2.6
Indicators of cardiovascular disease
Hyperlipidemia 66.3 51.7*
Hypertension 65.4 56.3*
Arrhythmia/conduction-related events 30.4 30.3
Ischemic heart disease 12.7 10.4*
Congestive heart failure 3.5 3.3
Hypertriglyceridemia 3.0 2.0*
Acute coronary syndrome 1.1 1.0
Other comorbidities
Arthritis 16.6 13.7*
Obesity 16.2 9.1*
Mean Charlson Comorbidity Index (CCI) (%) 1.6  1.1 1.3  1.3*
Mean total number of glucose-lowering agents
used in pre-exposure period (%) 1.9  1.1 0.6  0.9*
Use of glucose-lowering medication (within 30
days before index date)
Combination therapy 57.4 15.4*
Metformin only 13.6 10.3*
Sulfonylurea only 3.2 6.6*
TZD only 3.1 3.6*
Insulin only 5.3 2.9*
Use of other medications (recorded prescription)
Antihypertensive agents 77.8 57.8*
Antihyperlipidemic agents 63.8 39.3*
HMG-CoA reductase inhibitors (statins) 49.4 30.9*
ACE inhibitors 36.0 24.1*
Nonsteroidal anti-inﬂammatory drugs 23.2 18.7*
Angiotensin-receptor blockers 16.6 8.9*
Fibrates 12.9 6.6*
Data are percent or means  SD unless otherwise indicated. *P  0.001 exenatide vs. non-exenatide.
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P0.001)comparedwithnon-exenatide
initiators.
Consistent with the reduced fre-
quency of CVD events, exenatide initia-
tors had lower rates of hospitalization for
CVD-related events (HR 0.88; 0.79–
0.98; P  0.02) during the follow-up pe-
riod compared with the non-exenatide
initiators and had a lower rate of all-cause
hospitalization(HR0.94;0.91–0.97;P
0.001).
CONCLUSIONS — In a “real world”
cohort of patients with type 2 diabetes,
use of exenatide twice daily was associ-
ated with a reduced risk for CVD events
and CVD-related hospitalization. The
ﬁnding that the associated risk reduction
is robust using multiple statistical ap-
proaches gives credibility to the observa-
tion of reduced CVD risk. The
observation that lipid levels, blood pres-
sure, obesity, and evidence of prior CVD
were higher in patients initially treated
with exenatide than in patients initially
treated with other agents lends additional
support to the concept that exenatide use
is associated with favorable effects on
CVD outcomes and hospitalization com-
paredwithothertherapies.Thesedataare
consistent with the hypothesis that the
GLP-1 receptor agonist exenatide may re-
duce the risk for CVD in patients with
type 2 diabetes.
Several factors may explain the ob-
served reduction in CVD events and hos-
pitalization in exenatide versus non–
exenatide-treated patients: greater
reduction of hyperglycemia with less hy-
poglycemia and/or improvement in CVD
risk factors, including weight, lipids, and
blood pressure (14). A randomized con-
trolled clinical trial of the cardiovascular
outcomes associated with long-term use
of exenatide is needed to demonstrate
whether exenatide treatment reduces
CVD risk and to determine whether
changes in A1C, the incidence of hypo-
glycemia, and/or reductions in CVD risk
factors are associated with improved car-
diovascular outcomes.
Although observational studies have
generally shown a relationship between
hyperglycemia (even below the threshold
for the diagnosis of type 2 diabetes) and
CVD (1–3), clinical trials have not consis-
tently conﬁrmed that reducing hypergly-
cemia reduces CVD (4–9). The UK
Prospective Diabetes Study (UKPDS) re-
portedasigniﬁcantreductioninMIinthe
small cohort treated with metformin (6),
but effects with sulfonylureas and insulin
did not achieve statistical signiﬁcance un-
til the 10-year follow-up study (7,8).
Three large recently completed inter-
vention trials (Veterans Affairs Diabetes
Trial[VADT],ActiontoControlCardio-
vascular Risk in Diabetes [ACCORD],
and Action in Diabetes and Vascular Dis-
ease: Preterax and Diamicron–MR Con-
trolled Evaluation [ADVANCE]) did not
show evidence of CVD risk reduction in
the primary outcome (nonfatal MI, non-
fatal stroke, or death from cardiovascular
causes)(4,5,9).Infact,ACCORDwaster-
minated early because of increased all-
cause mortality in the intensive glycemic
treatment arm (5). Of note, the increased
mortality in each of the ACCORD arms
was associated with hypoglycemia (17).
Although the systematic review by Kelly
et al. (13) suggests that when the data from
UKPDS, ACCORD, ADVANCE, and VADT
are combined, the reduction in CVD
events becomes statistically signiﬁcant,
the effect is small. These observations
from ACCORD and VADT suggest that
whenthereisaneedtointensifyglucose
control, hypoglycemia may increase
CVD risk and counter the beneﬁts of
reducing hyperglycemia.
The primary strength of this study
was the inclusion of patients with type 2
diabetes who received glucose-lowering
therapyinareal-worldpopulation,alarge
and broadly representative source popu-
lation. This study reﬂects common clini-
cal practice across the U.S. and provides
for more than adequate statistical power
and information to adjust for potential
confounders. However, the administra-
tive data used in this real-world study
presentchallengesofaccuratelyascertain-
ing variables of interest. Although we
sought to mitigate potential sources of
bias in the conduct of this study, some
limitations remain, including potential
misclassiﬁcation of exposure and/or out-
come, and the potential for residual con-
founding. Diagnosis of CVD using ICD-
9-CM codes may not always represent a
clinical diagnosis of the disease; however,
prior publications indicate that the esti-
mated predictive value of administrative
data for identifying cardiovascular end
points are high (95% for acute MI and
stroke), suggesting that ICD-9-CM codes
have good positive predictive value
(18,19). In studies based on administra-
tive data, the misclassiﬁcation might be
assumed to be nondifferential with re-
spect to exposure, with a bias in the HR
toward the null value that might obscure
an association between exenatide and
CVDrisk.However,ifphysiciansmonitor
morecloselypatientswithseverediabetes
(who are more likely to be on exenatide)
forCVD,thentheestimatedassociationof
exenatide with CVD would be biased
away from the null.
Wecontrolledforalargesetoffactors
that potentially differed between the
groups at baseline using propensity score
methodology. Nevertheless, the incom-
plete capture of variables in the claims
data, such as weight, smoking, alcohol
consumption, and change in other vari-
ables associated with CVD risk (e.g., lip-
ids, blood pressure, and A1C), is a
limitation of the present analysis. Indeed,
the baseline characteristics of the study
cohorts suggest that exenatide initiators
have a higher prevalence of potential risk
factors for CVD, such as obesity, hyper-
tension, and hyperlipidemia. The direc-
Figure 2—HRs for cardiovascular events among the exenatide twice daily study cohort versus
nonexenatidestudycohortresultingfromvariousmethodologicaltechniques.Errorbarsrepresent
95%CIs.Propensity-ScoreStratiﬁed,propensityscore,stratiﬁedbydecile;ITT,intentiontotreat.
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captured variables suggests that remain-
ing (unmeasured) confounding would
lead to a higher risk of CVD among ex-
enatide users. However, baseline labora-
tory data and measures of CVD risk
markers such as weight, blood pressure,
and lipids are needed to adjust for popu-
lation differences, and we do not have
these data. We expect that adjustment for
the preindex clinical characteristics in-
cludinguseofantihyperlipidemicandan-
tihypertensive medications serve as
proxies for these variables.
Additionally, the linkage between
pharmacy submission of claims and pa-
tients’ receipt and consumption of the
medication is assumed and not directly
measured; prior work suggests that med-
ication exposure measures can be accu-
rately derived from pharmacy claims
(20).Asaninsurancedatabase,theresults
aremostgeneralizabletosimilarcommer-
cially insured patients, but the results are
likely to be relevant to a more general
population of patients with type 2 diabe-
tes, unless uninsured patients differ in
their response to exenatide.
This study does not address potential
questions about whether nonexenatide
agents may be associated with increased
risk (with possible absence of beneﬁt
from exenatide) or neutral risk of CVD
events.
In conclusion, in this retrospective
epidemiological study, exenatide-treated
patients were 19% less likely to have a
CVD event than patients treated with
otherglucose-loweringagents;exenatide-
treatedpatientswerealsolesslikelytoex-
perience CVD-related and all-cause
hospitalization. The results were robust
with respect to the statistical method and
supporttheCVDsafetyofexenatidetwice
daily for patients with type 2 diabetes.
The improved CV outcomes observed in
this retrospective database analysis need
to be conﬁrmed in prospective studies of
treatment with exenatide.
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